@oncbrothers.bsky.social - Oncology Brothers

10 Apr 2025 22:02 +0000

#Cabozantinib is now approved in #NET based off #CABINET study! We discussed the design, findings, sequencing, and AEs with Dr. Aman Chauhan (full discussion and one page takeaway 👇👇) Full 🗣️: ⭐️ Oncbrothers.com/cabinet ⭐️ Also on the “Oncology Brothers” podcast #OncSky #MedSky #GiOnc

07 Apr 2025 02:23 +0000

Less than 2 months to #ASCO25! Join us to discuss the current SoC➕how the data from #ASCO25 will change/reinforce our practice! ⭐️ InPerson: May 31st, 2025 ⭐️ Location📍Marriott Marquis ⭐️ Time: 6:30-9:00PM ⭐️ Register bit.ly/aioasco25 #AdvInOnc25 #OncSky

22 Feb 2025 16:34 +0000

#Zolbetuximab was approved based off #GLOW & #SPOTLIGHT (one page/slide summary attached)! We discussed the design, findings, sequencing and AEs/management w/ #KoheiShitara Full Discussion: ⭐️ http://Oncbrothers.com/zolbetuximab-fda-2025 ⭐️ Also on the “Oncology Brothers” podcast #gism #CanSky #OncSky

18 Feb 2025 02:15 +0000

Treatment Algorithm series: discussion on HER2+ #BreastCancer ✅ APT data/TCHP ✅ Metastatic disease ✅ Her2/ER/PR+ Full discussion: ⭐️ http://oncbrothers.com/her2positive-2025 ⭐️ https://www.cancernetwork.com/treatment-algorithms-with-the-oncology-brothers/her2-breast-cancer-treatment-algorithm ⭐️ “Oncology Brothers” podcast #bcsm #CancerSky #OncSky @drsarahsammons.bsky.social

11 Feb 2025 00:31 +0000

Treatment Algorithm series: starting off w/ TNBC discussion @vkaklamani.bsky.social ✅ Early disease ✅ ≥T2 or N+ disease ✅ Metastatic disease ✅ Low ER/PR+ Full 🗣️: ⭐️ https://oncbrothers.com/how-to-treat-triple-negative-breast-cancer-discussion-with-dr-virginia-kaklamani ⭐️ https://www.cancernetwork.com/treatment-algorithms-with-the-oncology-brothers/triple-negative-breast-cancer-treatment-algorithm ⭐️ “Oncology Brothers” podcast #bcsm #BreastCancer

06 Feb 2025 23:23 +0000

🚨In <1 wk, it’s #GU25🚨 Let’s discuss the current SoC ➕ how the data will change/reinforce our practice at #AdvInOnc25: - Bladder Ca - Prostate Ca - RCC *Join us LIVE* 📅 Date: Feb 12, 2025 ⏰ Time: 6:00-8:00PM 📝 bit.ly/guaio25 #OncSky #MedSky #gusm #Oncology #Cancer #CanSky

06 Feb 2025 02:55 +0000

AMPLIFY for 1L CLL now in @nejm.org 🔑 takeaways: 1️⃣ Fixed-duration #acalabrutinib + #venetoclax (±obinutuzumab) improved PFS (3-year): 76% (A+V), 83% (AVO) vs 66% (Chem) 2️⃣ AVO showed deeper responses but higher infection risk 3️⃣ New SoC for many #OncSky #CanSky #HemeSky

25 Jan 2025 23:12 +0000

#GI25 highlights #CommunityOnc: 1. #SCIENCE: Adv Eso SCC 2. #ESOPEC publication (Eso/GEJ/Ga) 3. Chemo in resectable Panc Ca 4. #StarterNET: GEP-NET 5. #CM8HW: dMMR/MSI-H mCRC 6. #BREAKWATER: BRAFV600E mCRC 7. ctDNA: #BESPOKE + SWOG80702 #OncSky #gism @ascocancer.bsky.social 1/8

17 Jan 2025 18:36 +0000

Datopotamab deruxtecan now #FDA approved off #TROPIONBreast01: #DatoDXd Vs Chemo post 1-2L HR+ mBC - ⏰ to 1st Rx: 8.2 vs 5mos (favoring Dato) - ⬆️ PFS 6.9mos vs 4.5 mos - Better AE + QoL favoring DatoDXd - AEs: Fatigue, infusion reactions, stomatitis #bcsm #OncSky #MedSky

03 Jan 2025 01:28 +0000

#GISeries: #Zanidatamab was recently approved based off #HerizonBTC01! We 🗣️ design, findings, sequencing and AEs/management with Dr. Shubham Pant Full Discussion: - http://Oncbrothers.com/zanidatamab-2024 - Also on the “Oncology Brothers” podcast #OncSky #MedSky #gism #GI25